UY36311A - Indazoles sustituidos con bencilo - Google Patents

Indazoles sustituidos con bencilo

Info

Publication number
UY36311A
UY36311A UY0001036311A UY36311A UY36311A UY 36311 A UY36311 A UY 36311A UY 0001036311 A UY0001036311 A UY 0001036311A UY 36311 A UY36311 A UY 36311A UY 36311 A UY36311 A UY 36311A
Authority
UY
Uruguay
Prior art keywords
indazols
bencilo
replaced
compounds
formula
Prior art date
Application number
UY0001036311A
Other languages
English (en)
Spanish (es)
Inventor
Hans-Georg Lerchen
Earwed Cleve
Wilhelm Bone
Ursula Mönning
Manfred Möwes
Lars Bärfacker
Hans Briem
Gerhard Siemeister
Joachim Kuhnke
Marion Hitchcock
Anne Mengel
Amaury Ernesto Fernandez-Montalvan
Simon Holton
Thomas Müller
Jens SCHRÖDER
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY36311A publication Critical patent/UY36311A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001036311A 2014-09-19 2015-09-18 Indazoles sustituidos con bencilo UY36311A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14185604 2014-09-19
EP15176903 2015-07-15

Publications (1)

Publication Number Publication Date
UY36311A true UY36311A (es) 2016-04-29

Family

ID=54140475

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036311A UY36311A (es) 2014-09-19 2015-09-18 Indazoles sustituidos con bencilo

Country Status (27)

Country Link
US (1) US10350206B2 (https=)
EP (1) EP3194379A1 (https=)
JP (1) JP6664385B2 (https=)
KR (1) KR20170049604A (https=)
CN (1) CN107001331A (https=)
AP (1) AP2017009803A0 (https=)
AU (1) AU2015316796A1 (https=)
BR (1) BR112017005444A2 (https=)
CA (1) CA2961589A1 (https=)
CL (1) CL2017000654A1 (https=)
CO (1) CO2017002532A2 (https=)
CR (1) CR20170100A (https=)
CU (1) CU20170029A7 (https=)
DO (1) DOP2017000078A (https=)
EA (1) EA032401B1 (https=)
EC (1) ECSP17016797A (https=)
IL (1) IL251071A0 (https=)
MA (1) MA39484A (https=)
MX (1) MX2017003664A (https=)
NI (1) NI201700034A (https=)
PE (1) PE20170697A1 (https=)
PH (1) PH12017500509A1 (https=)
SG (1) SG11201702082VA (https=)
TN (1) TN2017000092A1 (https=)
TW (1) TW201615636A (https=)
UY (1) UY36311A (https=)
WO (1) WO2016042084A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
JP2016525076A (ja) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
CN105452237A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
KR102352388B1 (ko) 2014-02-06 2022-01-17 헵테얼즈 테라퓨틱스 리미티드 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물
AR100886A1 (es) 2014-06-17 2016-11-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
MA39484A (fr) 2014-09-19 2016-03-24 Bayer Pharma AG Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
JP7090639B2 (ja) 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
IL129416A0 (en) 1996-10-14 2000-02-17 Bayer Ag New heterocyclylmethyl-substituted pyrazol derivatives
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
WO2003051833A2 (en) 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
JP2006503043A (ja) 2002-09-10 2006-01-26 サイオス インク. TGFβ阻害剤
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
CA2687306A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
EP2373626B1 (en) 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
EP2491033A4 (en) 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
PH12012501023A1 (en) 2009-11-27 2014-12-19 Adverio Pharma Gmbh Method for producing methyl - {4, 6-diamino -2-[1- (2-fluorobenzyl) -1h- pyrazolo [3,4-b] pyridino -3-yl] pyrimidino -5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
WO2013167698A1 (en) 2012-05-11 2013-11-14 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
EP2976334A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
EP2976335A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
EP2976336A1 (en) 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
JP2016525076A (ja) 2013-06-21 2016-08-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたベンジルピラゾール類
CN105452237A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 杂芳基取代的吡唑
JP2016526540A (ja) 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール
WO2014202588A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
WO2014202586A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
CA2928998A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
EA033697B1 (ru) 2014-09-19 2019-11-18 Glaxosmithkline Ip Dev Ltd Активаторы растворимой гуанилатциклазы и их применение
MA39484A (fr) 2014-09-19 2016-03-24 Bayer Pharma AG Indazoles à substituants benzyle utilisés comme inhibiteurs de bub1
WO2016042080A1 (en) 2014-09-19 2016-03-24 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
WO2016042518A1 (en) 2014-09-19 2016-03-24 Nestec Sa Treatment of cancer with alpha-amylase inhibitor in companion animals
CA2961570A1 (en) 2014-09-19 2016-03-24 Lars Barfacker Benzyl substituted indazoles
WO2016044789A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP2017529353A (ja) 2014-09-19 2017-10-05 バイエル ファーマ アクチエンゲゼルシャフト Bub1キナーゼ阻害薬としてのベンジル置換インダゾール類
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Also Published As

Publication number Publication date
CO2017002532A2 (es) 2017-07-11
NI201700034A (es) 2017-06-16
US20170273980A1 (en) 2017-09-28
CA2961589A1 (en) 2016-03-24
IL251071A0 (en) 2017-04-30
KR20170049604A (ko) 2017-05-10
AU2015316796A1 (en) 2017-03-30
EP3194379A1 (en) 2017-07-26
BR112017005444A2 (pt) 2018-04-24
PE20170697A1 (es) 2017-06-24
TW201615636A (zh) 2016-05-01
EA032401B1 (ru) 2019-05-31
CN107001331A (zh) 2017-08-01
MX2017003664A (es) 2017-07-13
CU20170029A7 (es) 2017-08-08
EA201790649A1 (ru) 2017-09-29
MA39484A (fr) 2016-03-24
WO2016042084A1 (en) 2016-03-24
JP6664385B2 (ja) 2020-03-13
CR20170100A (es) 2017-04-24
AP2017009803A0 (en) 2017-03-31
CL2017000654A1 (es) 2017-12-11
DOP2017000078A (es) 2017-06-30
PH12017500509A1 (en) 2017-08-30
ECSP17016797A (es) 2017-05-31
TN2017000092A1 (en) 2018-07-04
JP2017530962A (ja) 2017-10-19
US10350206B2 (en) 2019-07-16
SG11201702082VA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
UY36311A (es) Indazoles sustituidos con bencilo
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CO2017006960A2 (es) Uso de picolinamidas como fungicidas
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2017001393S1 (es) Automovil
CL2017001185S1 (es) Automovil
ECSP17015977A (es) Terapia de combinacion
UY36480A (es) Uso de compuestos de picolinamida como fungicidas
TWD174683S (zh) 戒指
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
MX2021001231A (es) Compuestos heterociclicos y sus usos.
UY35500A (es) Indazoles sustituidos con heteroarilo
TWD168962S (zh) 針盤
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
CL2016000597A1 (es) Derivados de desoxino jirimicina y sus métodos de uso.
TWD171710S (zh) 端子
MX2014015039A (es) Inhibidores de fbx03.
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MY167383A (en) Disposable diaper
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
UY37383A (es) Picolinamidas como fungicidas
TWD171709S (zh) 端子

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220712